TBPH – theravance biopharma, inc. - ordinary shares (US:NASDAQ)

News

Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma to Participate in an Upcoming Investor Conference
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com